Allogeneic bone marrow transplantation for a subset of children with acute lymphoblastic leukemia in third remission: a conceivable alternative?

Bone Marrow Transplantation
A BorgmannGünter Henze

Abstract

In the BFM Relapse Study registry we retrospectively identified 136 patients with a first marrow relapse who had undergone BMT in second complete remission (CR2) (group A) and 33 patients who received transplants only after a 2nd bone marrow (BM) relapse had occurred (group B). Event-free survival (EFS) rates at 6 years after BMT were 0.49 +/- 0.05 and 0.48 +/- 0.09 for patients transplanted in CR2 and CR3, respectively. In context with the BFM chemotherapy trials for relapsed childhood ALL there is a clear benefit from BMT in 2nd CR for children with unfavorable prognostic features (isolated early BM relapse, very early BM relapse or BM relapse of T cell ALL). Similar control of leukemia can be achieved with either chemotherapy or BMT in late BM relapse of ALL. Assuming a 60% failure rate with chemotherapy for patients in second relapse, a third remission can be achieved in about 60% of patients who have received chemotherapy, rendering them eligible for BMT in 3rd CR. With this strategy 58% of these patients would survive and late sequelae of BMT be restricted to a minority. To withhold BMT in CR2 and not perform BMT before a 2nd BM relapse has occurred, may be a conceivable alternative for children with late ALL BM relapse, ...Continue Reading

Citations

Nov 13, 2007·Bone Marrow Transplantation·P A Mehta, S M Davies
Aug 8, 1998·British Journal of Haematology·J M Chessells
Jun 26, 2003·British Journal of Haematology·Nick GouldenJacques Van Dongen
Oct 26, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Arend von StackelbergUNKNOWN ALL-REZ BFM Study Group
Nov 18, 2003·British Journal of Haematology·Judith M ChessellsIan M Hann
Sep 11, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Michael J BurkeMichael R Verneris
Jun 21, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Eneida R NemecekPaul A Carpenter
Apr 10, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Michael J BurkeMichael R Verneris
May 21, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Paul D Harker-MurrayPaul J Orchard
Nov 9, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Theresa HahnPhilip L McCarthy
Jul 28, 2009·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Marina KonoplevaMichael Andreeff
Apr 30, 2003·European Journal of Internal Medicine·Tomasz WróbelKazimierz Kuliczkowski
Dec 21, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ulla M Saarinen-PihkalaGöran Gustafsson
May 3, 2002·Japanese Journal of Cancer Research : Gann·Norihide SatoYasuo Ikeda
Jun 6, 2008·International Journal of Cancer. Journal International Du Cancer·Qiming SunZi-Chun Hua
Mar 19, 2016·Intractable & Rare Diseases Research·Yang HanGuosheng Jiang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.